Pharmaids Pharmaceuticals' Q4 FY 2025-26 Quarterly Results

Result Summary

• Pharmaids Pharmaceuticals Ltd reported a 32.1% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Mar (Q4 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 50.4%.
• Its expenses for the quarter were down by 5.3% QoQ and 16.1% YoY.
• The net profit decreased 58.9% QoQ and decreased 77.3% YoY.
• The earnings per share (EPS) of Pharmaids Pharmaceuticals Ltd declined at 0.51 during Q4 FY 2025-26.

Financial Statments for Q4 FY 2025-26

---

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Pharmaids Pharmaceuticals Ltd is a company operating in the pharmaceutical industry. The company is primarily engaged in the manufacturing and distribution of pharmaceutical products. Information about the specific products or services, recent major developments, or strategic changes is not available within the current data set. As a player in the pharmaceutical sector, the company's performance may be influenced by industry trends, regulatory changes, and market demand for its offerings.

Revenue

In Q4FY26, Pharmaids Pharmaceuticals Ltd reported a total income of ₹7.28 crores, representing a significant increase from the previous quarter (Q3FY26) where the total income was ₹5.51 crores. This reflects a quarter-over-quarter (QoQ) growth of 32.1%. Comparing year-over-year (YoY), the total income increased from ₹4.84 crores in Q4FY25, marking a 50.4% rise. This substantial YoY growth indicates an upward trend in the company's revenue generation capabilities during this period.

Profitability

Pharmaids Pharmaceuticals Ltd's profitability metrics reveal a notable improvement in Q4FY26. The Profit Before Tax (PBT) for this quarter was reported at -₹1.46 crores, which shows an improvement from -₹4.02 crores in Q3FY26, indicating a QoQ change of -63.7%. Year-over-year, the PBT improved from -₹5.40 crores in Q4FY25, showing a YoY improvement of -73.0%. The Profit After Tax (PAT) also showed progress, with Q4FY26 reporting -₹1.09 crores compared to -₹2.65 crores in Q3FY26, marking a QoQ improvement of -58.9%. Compared to Q4FY25, where the PAT was -₹4.80 crores, there is a YoY improvement of -77.3%. Despite the negative profitability figures, the company has shown significant progress in reducing its losses.

Operating Metrics

The total expenses for Pharmaids Pharmaceuticals Ltd in Q4FY26 amounted to ₹8.65 crores, which is a decrease from ₹9.13 crores in Q3FY26. This represents a QoQ reduction of -5.3%. Comparing year-over-year, total expenses declined from ₹10.31 crores in Q4FY25, reflecting a YoY decrease of -16.1%. Earnings Per Share (EPS) for Q4FY26 was reported at -₹0.51, improving from -₹0.70 in Q3FY26, with a QoQ change of -27.1%. Year-over-year, EPS improved from -₹1.11 in Q4FY25, marking a YoY enhancement of -54.1%. These metrics indicate that the company has made strides in managing its operating expenses and improving its earnings per share, despite the negative values.